Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Novel agents for thrombotic disorders imparted by AstraZeneca

Aug. 31, 2005

Enrollment opens in phase II heparin replacement study for rNAPc2

Aug. 25, 2005

Betaine displays anticoagulant activity in healthy individuals

Aug. 24, 2005

LK-732: A direct thrombin inhibitor effective in preclinical models of venous thrombosis

Aug. 24, 2005

Patents report therapeutic agents for thrombotic disorders

Aug. 24, 2005

NN-1731 offers a better hemostatic potential than recombinant FVIIa

Aug. 23, 2005

Efficacy and safety data for otamixaban from preclinical studies

Aug. 22, 2005

Anticoagulant and antiinflammatory effects of rhAT in healthy volunteers

Aug. 18, 2005

Antithrombotic efficacy of dual-acting MC-45308

Aug. 18, 2005

Phase II data on rhThrombin in the management of postoperative bleeding

Aug. 17, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...